lekoksportief schreef op 16 december 2020 11:55:
SYDNEY, AUSTRALIA – December 16, 2020 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or
“the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and
autoimmune diseases, has prioritised the recommencement of the process of scaling up the manufacturing
of its lead product candidate eftilagimod alpha (“efti” or “IMP321”).
This follows the very encouraging interim results Immutep announced from its efti clinical trials at SITC (10
November 2020) and SABS (10 December 2020) and will be funded by the recent conversion of warrants on
Immutep.
Immutep is planning to increase the efti manufacturing process from 200L to 2,000L capacity bioreactors at
the WuXi Biologics manufacturing plant (Mashan site, Wuxi, China), with the major scale up stepstaking place
throughout 2021.
Chris Chen, CEO of WuXi Biologics said: “We are very pleased to be moving the scale up process forward for
efti with Immutep. WuXi Biologics and Immutep have been working together for many years and we are
excited to continue supporting them as they advance towards registration for efti.”
Marc Voigt, CEO of Immutep said: “Following the very encouraging interim Overall Survival data announced
last week from our largest clinical trial, AIPAC, we have activated our plans to upscale the manufacturing of
efti to 2,000L single-use bioreactors to prepare for potential commercial manufacturing and potential
registration trials in multiple indications. WuXi Biologics is an important and long-term partner for us with
excellent technical and commercial capabilities. We are entering 2021 in a very strong position, both
financially and operationally.”